BSc (Hons), MBBS (Hons) MEd MRCP
Novo Nordisk Clinical Research Training Fellow & DPhil Student
I am a Specialist Registrar and Clinical Research Fellow in Diabetes, Endocrinology and Metabolism. My undergraduate training was undertaken at Imperial College London from where I hold a BSc in Pharmacology and Toxicology and graduated in Clinical Medicine with Distinction. As part of my postgraduate training, I was awarded NIHR Academic Clinical Fellowships at Imperial College London and at Bart’s and the London School of Medicine through which I pursued research in obesity and metabolism alongside my clinical practice. I also have considerable experience in medical education and clinical leadership and hold a Master’s in Education (MEd). Between 2010-11, I worked on secondment at the Department of Health as a Clinical Advisor to the National Medical Director for the NHS in England where my portfolio included work on quality improvement and clinical leadership within the NHS.
My research during this fellowship is focused on non-alcoholic fatty liver disease (NAFLD), which is becoming the most common cause of chronic liver disease worldwide and affects up to 70% of patients with Type 2 Diabetes. Based at OCDEM and OCMR, I have established a clinical trial to investigate the utility of GLP-1 agonists as novel therapeutic agents for patients with NAFLD. Additionally, through this and related clinical studies, I am also investigating the use of the urinary steroid metabolome as a novel non-invasive diagnostic tool with which to diagnose and stage NAFLD and to assess treatment response.
Liver biochemical abnormalities in Turner syndrome: A comprehensive characterization of an adult population.
Calanchini M. et al, (2018), Clin Endocrinol (Oxf)
Prevalence and severity of non-alcoholic fatty liver disease are underestimated in clinical practice: impact of a dedicated screening approach at a large university teaching hospital.
Marjot T. et al, (2018), Diabet Med, 35, 89 - 98
l-phenylalanine modulates gut hormone release and glucose tolerance, and suppresses food intake through the calcium-sensing receptor in rodents.
Alamshah A. et al, (2017), Int J Obes (Lond), 41, 1693 - 1701
High risk populations: Attitudes to NAFLD among Diabetologists
Marjot T. et al, (2016), HEPATOLOGY, 64, 557A - 557A
L-arginine promotes gut hormone release and reduces food intake in rodents.
Alamshah A. et al, (2016), Diabetes Obes Metab, 18, 508 - 518